| Outcome | Nilotinib group (n = 25) | Imatinib group (n = 25) | P value |
| At the 12th month |
|
|
|
| Major molecular response | 20 (80) | 18 (72) | 0.04* |
| Type of response |
|
| 0.01* |
| Optimal | 12 (48) | 11 (44) |
|
| Early moleculr | 8 (32) | 7 (28) |
|
| Warning | 5 (20) | 7 (28) |
|
| At the 18th month |
|
|
|
| Major molecular response | 22 (88) | 16 (64) | 0.02* |
| Type of response |
|
| 0.02* |
| Optimal | 12 (48) | 9 (36) |
|
| Earlymolecular | 10 (40) | 7 (28) |
|
| Warning | 3 (6) | 9 (36) |
|
| At the end of the study |
|
|
|
| Major molecular response |
| 16 (64) | 0.01* |
| Type of response |
|
| 0.04* |
| Optimal |
| 6 (24) |
|
| Early molecular |
| 10 (40) |
|
| Warning |
| 9 (36) |
|